Chamath Palihapitiya
· Chamath Palihapitiya
· May 24, 2026 at 16:38
· ⏱ 5 min read
| Read on Substack ↗
Summary
Chamath Palihapitiya summarizes three major developments: Eli Lilly's retatrutide shows 28% weight loss in Phase 3, positioning it as a potential blockbuster; NextEra Energy acquires Dominion Energy for $67B to scale for AI-driven power demand; SpaceX files for a record $1.75T IPO with Starlink, launch, and xAI revenues, though losses are substantial. No trade ideas or personal positions are disclosed.
•Eli Lilly's retatrutide achieved 28.3% average weight loss in a 2,339-patient Phase 3 trial, with 65.3% of patients falling below the obesity BMI cutoff and 45.3% losing at least 30% weight.
•Retatrutide is the first triple agonist (GLP-1, GIP, glucagon) and showed no cardiac or liver side effects in this trial.
•NextEra Energy agreed to buy Dominion Energy for $67B in an all-stock deal, creating a combined company worth ~$249B market cap and ~$420B enterprise value.
•The merger positions the combined entity as the third-largest U.S. energy company, critical for serving data center power demand expected to consume 17% of U.S. electricity by 2030.
•SpaceX publicly filed for a $1.75T valuation IPO targeting $75B raise, with 2025 revenue of $18.7B and $4.94B loss; Starlink is the only profitable segment with $4.4B operating income.
•xAI (Grok, X platform) generated $3.2B revenue with a $6.4B loss and $12.7B capex; SpaceX committed Colossus 1 capacity to Anthropic at $1.25B/month through May 2029.